Transforming Revision Surgery.

Amotio is pleased to announce that we will be attending the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting this March in New Orleans.

A central focus of our visit will be to connect with arthroplasty and revision surgeons, particularly those working with cemented techniques in complex joint reconstruction. Amotio is developing a patient-specific solution designed to address the ongoing challenge of safe, accurate and efficient removal of bone cement during revision surgery. We are keen to discuss current clinical workflows, unmet needs, and how personalised planning and instrumentation may support improved surgical precision, efficiency and confidence for the operating team.

Alongside clinical engagement, AAOS provides an important opportunity for Amotio to meet with experienced sales agents and distributor partners operating within the US orthopaedic market. As an early-stage company preparing for international expansion, we are seeking aligned commercial partners who share our focus on clinical value, quality systems and responsible market development.

Attending AAOS marks a defining moment for Amotio. From our foundations in the Netherlands and Wales, UK , this first step onto the US stage reflects both the strength of our progress and our ambition to contribute meaningful innovation to revision arthroplasty on a global scale. If you are attending AAOS in March and would like to meet with the Amotio team, whether as a surgeon, clinical leader or commercial partner, we would welcome the opportunity to connect and continue the conversation.

You can find the Amotio team at Booth 746

Amotio has achieved ISO 13485 certification, formally recognising the quality management system that underpins how we design, develop, and operate as a medical device company.

Quality at Amotio is embedded across the entire organisation and reflected in every design decision, process, and interaction. Through this accreditation, we reaffirm our commitment to the standards and foundations upon which the company is built, strengthening our responsibility to patients, clinicians, and healthcare systems.

This achievement also serves as a foundation for continuous improvement, ensuring that our practices evolve to meet the highest levels of safety, reliability, and performance.

Amotio is pleased to announce the appointment of Jon Selby as Principal Design Engineer, who joined the company in January 2026. Jon is a highly experienced medical device design engineer with a strong commitment to improving patient outcomes and clinician experience through rigorous, user-centred engineering. He joins Amotio from a senior role developing a Class III implantable neurological drug delivery system, where his responsibilities spanned concept development, detailed design, risk management, usability engineering, and progression into clinical use.

A defining feature of Jon’s experience has been close collaboration with clinicians in theatre, providing real-world context that directly informed and strengthened device usability, safety, and design decision-making.

Jon’s background is deliberately broad. He began his career working with a leading consumer and healthcare showering brand, before progressing through precision metrology and ultimately finding his passion in medical device design. This pathway has given him a deep appreciation of manufacturing technologies and a strong focus on design for manufacture and reliable scale-up.

Commenting on the appointment, Iestyn Foster, CEO & Co-Founder of Amotio, said:
“We’re delighted to welcome Jon to Amotio. His depth of experience across complex medical devices, combined with a strong user-centred mindset, strengthens our capability as we move toward production-ready systems.” Jon has joined Amotio at a pivotal stage of development and is now focused on advancing the company’s device designs from functional prototypes into robust, production-ready products.